Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Dale TerasakiRyan LohAnastasia CornellJulie TaubChristian ThurstonePublished in: Addiction science & clinical practice (2022)
gov Identifier NCT04562779. Registered 24 September 2020. https://clinicaltrials.gov/ct2/show/NCT04562779.